View in EDS HTML Full Text PDF Full Text

Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis.

Saved in:
Bibliographic Details
Title: Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis.
Authors: Saidha, Shiv (AUTHOR), Bell, Judith (AUTHOR), Harold, Sydney (AUTHOR), Belisario, Jose Marcano (AUTHOR), Hawe, Emma (AUTHOR), Shao, Qiujun (AUTHOR), Wyse, Kerri (AUTHOR), Maiese, Eric M. (AUTHOR)
Source: Neurological Sciences. May2023, Vol. 44 Issue 5, p1515-1532. 18p. 1 Diagram, 3 Charts, 3 Graphs.
Subjects: Monoclonal antibodies, Multiple sclerosis, Time trials, Legal evidence, Crime & the press
Abstract: Objective: To exp lore changes in immunoglobulin (Ig) levels for people with relapsing-multiple sclerosis (RMS) treated with ocrelizumab or ofatumumab and the relationship between Ig levels and infections. Methods: A systematic literature review (SLR) was conducted to identify clinical trials and real-world evidence (RWE) studies on Ig levels over time and studies on associations with infections for ocrelizumab and ofatumumab for people with RMS through 10 September 2021. Searches were conducted in Embase, MEDLINE, Cochrane Library, trial registries, and recent conference abstracts. Results: Of 1,580 articles identified, 30 reporting on 11 trials and 5 RWE studies were included. Ocrelizumab trials (n = 4) had 24–336 weeks of follow-up and reported decreasing Ig G (IgG) levels, while RWE (n = 5) had 52–78 weeks of follow-up and reported IgG to be stable or decrease only slightly. IgG levels were stable in ofatumumab trials (n = 5; 104–168 weeks of follow-up), but no RWE or longer-term studies were identified. No apparent association between decreased Ig levels and infections was observed during ofatumumab treatment (ASCLEPIOS I/II), while for ocrelizumab, the only data on apparent associations between decreased IgG levels and serious infection rates were for a pooled population of people with RMS or primary progressive MS. Conclusion: Decreasing IgG levels have been correlated with increased infection risk over time. IgG levels appeared to decrease over time in ocrelizumab trials but remained relatively stable over time in ofatumumab trials. Additional research is needed to understand differences between ocrelizumab and ofatumumab and identify people at risk of decreasing IgG levels and infection. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 163099551
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Saidha%2C+Shiv%22">Saidha, Shiv</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bell%2C+Judith%22">Bell, Judith</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Harold%2C+Sydney%22">Harold, Sydney</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Belisario%2C+Jose+Marcano%22">Belisario, Jose Marcano</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hawe%2C+Emma%22">Hawe, Emma</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shao%2C+Qiujun%22">Shao, Qiujun</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wyse%2C+Kerri%22">Wyse, Kerri</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Maiese%2C+Eric+M%2E%22">Maiese, Eric M.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. May2023, Vol. 44 Issue 5, p1515-1532. 18p. 1 Diagram, 3 Charts, 3 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Monoclonal+antibodies%22">Monoclonal antibodies</searchLink><br /><searchLink fieldCode="DE" term="%22Multiple+sclerosis%22">Multiple sclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22Time+trials%22">Time trials</searchLink><br /><searchLink fieldCode="DE" term="%22Legal+evidence%22">Legal evidence</searchLink><br /><searchLink fieldCode="DE" term="%22Crime+%26+the+press%22">Crime & the press</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objective: To exp lore changes in immunoglobulin (Ig) levels for people with relapsing-multiple sclerosis (RMS) treated with ocrelizumab or ofatumumab and the relationship between Ig levels and infections. Methods: A systematic literature review (SLR) was conducted to identify clinical trials and real-world evidence (RWE) studies on Ig levels over time and studies on associations with infections for ocrelizumab and ofatumumab for people with RMS through 10 September 2021. Searches were conducted in Embase, MEDLINE, Cochrane Library, trial registries, and recent conference abstracts. Results: Of 1,580 articles identified, 30 reporting on 11 trials and 5 RWE studies were included. Ocrelizumab trials (n = 4) had 24–336 weeks of follow-up and reported decreasing Ig G (IgG) levels, while RWE (n = 5) had 52–78 weeks of follow-up and reported IgG to be stable or decrease only slightly. IgG levels were stable in ofatumumab trials (n = 5; 104–168 weeks of follow-up), but no RWE or longer-term studies were identified. No apparent association between decreased Ig levels and infections was observed during ofatumumab treatment (ASCLEPIOS I/II), while for ocrelizumab, the only data on apparent associations between decreased IgG levels and serious infection rates were for a pooled population of people with RMS or primary progressive MS. Conclusion: Decreasing IgG levels have been correlated with increased infection risk over time. IgG levels appeared to decrease over time in ocrelizumab trials but remained relatively stable over time in ofatumumab trials. Additional research is needed to understand differences between ocrelizumab and ofatumumab and identify people at risk of decreasing IgG levels and infection. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=163099551
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10072-022-06582-y
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 18
        StartPage: 1515
    Subjects:
      – SubjectFull: Monoclonal antibodies
        Type: general
      – SubjectFull: Multiple sclerosis
        Type: general
      – SubjectFull: Time trials
        Type: general
      – SubjectFull: Legal evidence
        Type: general
      – SubjectFull: Crime & the press
        Type: general
    Titles:
      – TitleFull: Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Saidha, Shiv
      – PersonEntity:
          Name:
            NameFull: Bell, Judith
      – PersonEntity:
          Name:
            NameFull: Harold, Sydney
      – PersonEntity:
          Name:
            NameFull: Belisario, Jose Marcano
      – PersonEntity:
          Name:
            NameFull: Hawe, Emma
      – PersonEntity:
          Name:
            NameFull: Shao, Qiujun
      – PersonEntity:
          Name:
            NameFull: Wyse, Kerri
      – PersonEntity:
          Name:
            NameFull: Maiese, Eric M.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 15901874
          Numbering:
            – Type: volume
              Value: 44
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Neurological Sciences
              Type: main
ResultId 1